KLK3 and metastatic neoplasm: However, there were no significant differences in prostate-specific antigen (PSA) levels, suggesting no significant difference in disease burden between the arms; while the authors did not specify the proportion of men in each arm with metastatic disease, baseline PSA levels were elevated in the range of 18–21 ng/mL and were similar between treatment arms.